User:Merely another passerby/sandbox

From Wikipedia, the free encyclopedia
A Breath of French Air
AuthorH. E. Bates
Cover artistJames Broom-Lynne
CountryUnited Kingdom
LanguageEnglish
SeriesThe Larkins
GenreComedy novel
PublisherMichael Joseph
Publication date
1959
Media typePrint (hardback & paperback)
Pages160
Preceded byThe Darling Buds of May 
Followed byWhen the Green Woods Laugh 

A Breath of French Air is a novella written by British author H. E. Bates, first published in 1959. It was the second of a series of five books about the Larkins, a rural family from Kent.

The title is a play on the expression "a breath of fresh air."

Pop and Ma Larkin and their many children take joy in nature, each other's company, and almost constant feasts. Their only income is through selling scrap, picking strawberries, and selling farm animals or previous purchases that they've tired of. Nevertheless, they joyfully spend money on horses, cars, perfume, fine furniture, and holidays abroad. Pop Larkin opposes taxes and any barriers to free enterprise.

Plot[edit]

Reception[edit]

Other literary reviews appeared in The Times[2] and New Statesman[3]

TV adaptation[edit]

ITV produced a television series of the Larkin novels plus additional original storylines, The Darling Buds of May, which ran from 1991 to 1993.

References[edit]

  1. ^ "Artwork by James Broom-Lynne". www.broom-lynne.com.
  2. ^ "New Fiction". The Times. August 20, 1959.
  3. ^ Mayne, Richard (August 29, 1959). "New fiction". New Statesman.

External links[edit]

Category:1959 British novels Category:British comedy novels A Breath of French Air Category:English novels Category:Novels set in Kent Category:Novels set in France Category:Michael Joseph books

ARIAs 2023[edit]

The nominees were announced on 30 March 2023. Two award categories were retired; Best Independent Podcast and Best Marketing Campaign, and replaced by four new categories; Best Community Station of the Year, Best Audiobook or Reading and a split of Best New Show into Best New Radio Show and Best New Podcast. In addition, Best Fictional Storytelling which in previous years had included readings became Best Drama. There was also a one-off 2022 Special Award recognising audio coverage following the death of Her Majesty Queen Elizabeth II, bringing the total number of awards to 28. A change of venue was also announced.[1]

On 21 April 2023 it was revealed that Tony Blackburn would be receiving The Pioneer Award for his near 60 years in broadcasting and contribution to the popularity of soul music in the UK.[2] Tony is only the second recipient of The Pioneer Award, following the late Janice Long receiving the inaugural award posthumously last year.[3] Tim Blackmore was announced as guest of honour at this years ceremony in recognition of his contribution to radio and audio over the past six decades.[4]

Presented: 2 May 2023 at The Theatre Royal, Drury Lane – Hosts: Rylan Clark with a live voice-over from Fleur East[1]
Best New Presenter Best New Radio Show Best News Coverage


Best Speech Breakfast Show Best Speech Presenter Best Sports Show
Best Music Breakfast Show Best Music Entertainment Show Best Specialist Music Show
The Comedy Award Best Factual – Single programme Best Factual – Series
The Grassroots Award Best New Podcast Best Station Sound
Best Commercial Partnership Best Music Special The Impact Award
Best Local Show John Myers Award for Local Station of the Year National Station or Network of the Year
Best Drama The Creative Innovation Award Best Coverage of an Event
Best Audiobook or Reading Community Station of the Year The 2022 Special Award (following the death of Her Majesty The Queen)
Radio Times Moment of The Year
The Pioneer Award
Tony Blackburn for almost 60 years in broadcasting and contribution to the popularity of soul music in the UK

Argenx[edit]

Argenx SE is an international biopharmaceutical company headquartered in the Netherlands, developing and commercialising humanized monoclonal antibody based therapies. It has major offices in Ghent, Belgium, Boston, USA and Tokyo, Japan as well as regional outposts in Canada, France, Germany and Switzerland.[5][6]

The company has many drugs in its wider pipeline that are being investigated in a variety of diseases areas. While some of these are being developed in partnership with pharmaceutical and biotech companies, Argenx also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

Argenx SE
FormerlyarGEN-X B.V.
Company typePublic Company
IndustryBiotechnology
Founded2008; 16 years ago (2008) in Utrecht, Netherlands
Founders
  • Tim van Hauwermeiren
  • Hans J. W. de Haard
  • Torsten Dreier
Headquarters
Breda
,
Netherlands
Area served
Worldwide
Key people
  • Tim van Hauwermeiren, CEO
  • Karl Gubitz, CFO
  • Keith Woods, COO
  • Hans J. W. de Haard, CSO
ProductsEfgartigimod
BrandsVyvgart
ServicesImmunotherapy
Revenue
  • Increase US$497.3 million (2021)
  • US$41.2 million (2020)
[6]
  • Increase US$539.4 million (2021)
  • US$64.9 million (2020)
[6]
  • Decrease US$(450.6 million) (2021)
  • US$(446.2 million) (2020)
[6]
Total assets
  • Increase US$2,850.3 million (2021)
  • US$2,279.4 million (2020)
[6]
Total equity
  • Increase US$2,534.2 million (2021)
  • US$1,674.0 million (2020)
[6]
Number of employees
854 [7] (end 2021)
Websiteargenx.com

History[edit]

The company was incorporated under the name arGEN-X B.V. in Rotterdam on April 25, 2008 by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren[5][6] on a ground-breaking antibody engineering discovery – using the diversity of the llama immune system to build differentiated human antibodies.[8] Seed financing of 1 million Euros was provided by Erasmus MC and Thuja Capital.[9]

The company name is inspired by the tale of the Argonauts and the philosophy that collaboration is key to success.[10][7] It has been listed since July 2014 on Euronext in Brussels and May 2017 on NASDAQ in New York, both under the ticker symbol “ARGX”.[11][12]

In 2011, Argenx and Eli Lilly & Company entered into a strategic partnership for the research and development of specific antibody targets[8]. A therapeutic antibody alliance with Shire followed in 2012, which was further expanded in 2013 and 2014. Additional partnerships included Boehringer Ingelheim (2013), Bayer (2014), Staten Biotechnology (January 2015), Leo Pharma (May 2015), AbbVie (April 2016) and Janssen-Cilag (December 2018).[6][9]

In 2013, the company’s lead proprietary antibody ARGX-113 entered clinical development.[13]

In December 2020, based on positive clinical trial results, the company submitted a Biologics License Application (BLA) to the FDA for the first of it's platform drugs, Efgartigimod (ARGX-113) for the treatment of generalised myasthenia gravis.[14] US marketing approval was granted by the FDA on 17 December 2021.[15] Filing in Japan with the PMDA took place in January 2021 with approval granted on January 20, 2022.[16] European filing with the EMA took place in August 2021 with the CHMP adopting a positive opinion and recommending the granting of a marketing authorisation on 23 June 2022.[17]

Technology[edit]

Argenx sources antibodies from outbred llamas (whose ‘v’ regions very closely resemble those of human antibodies but are much more potent) by using its SIMPLE Antibody™ platform.[8]

After fine-tuning the properties of the Fc regions of the antibodies using other technologies in its portfolio (NHance ® to extend the half-life/PD effect and enhance tissue penetration; ABDEG™ to clear disease target and autoantibodies; POTELLIGENT ® to boost the ability to kill targeted cells) the antibodies are introduced into the body of the patient. These new antibodies then strengthen and help the natural defences of the human body in order to exterminate, disable or weaken the proposed illnesses.[6][9]

Pipeline[edit]

Approved antibodies[edit]

Efgartigimod (formerly ARGX-113, brand name Vyvgart: target FcRN) is a first-in-class humanised monoclonal antibody treatment for generalised myasthenia gravis (gMG), a rare condition (200 people per million) that leads to the failure or insufficient functioning of the muscles.

In December 2021, efgartigimod was approved by the U.S. Food and Drug Administration to treat adults with gMG who are positive for anti-acetylcholine receptor (AChR) antibodies — the most common type of MG-causing antibody. The therapy also has been approved in Japan to treat adults with gMG, regardless of antibody status, who failed to respond to steroids or nonsteroidal immunosuppressive therapies.[6]

In addition to gMG, efgartigimod is being evaluated in several other autoimmune diseases known to be mediated by disease-causing IgG antibodies, including other neuromuscular disorders (Chronic Inflammatory Demyelinating Polyneuropathy, Idiopathic Inflammatory Myopathy), skin blistering diseases (Pemphigus Vulgaris and Foliaceus, Bullous Pemphigoid) and Immune Thrombocytopenia Purpura (ITP). ITP is a relatively rare blood disorder (incidence: 30 people per million) in which the blood does not clot well.[6][12]

Efgartigimod has been awarded orphan drug status in both the US and Europe.[15][17][18] The designation is given to therapies for rare diseases, which are classified in the US as a disorder affecting fewer than 200,000 people, and in the EU as diagnosed in not more than 5 in 10,000 people.[6][19]

Under development[edit]

Monclonal antibody (mAB) Other nomenclature Collaboration / out-licensing Target Indication / disease Clinical phase
ARGX-109[8] Gerilimzumab

/ GB224

Bird Rock Bio / Genor BioPharma IL-6 Rheumatoid Arthritis Phase I concluded
ARGX-110[12] Custuzumab Janssen-Cilag CD70 Acute Myeloid Leukemia (AML) and and higher-risk Myelodysplastic Syndromes (MDS) Phase I / II
ARGX-111[9] - c-Met Solid tumors and blood cancers Phase I concluded
ARGX-112[6] LP-0145 LEO Pharma IL-22R Atopic dermatitis Phase I
ARGX-114[6] AGMB-101 AgomAb Therapeutics MET Fibrotic, inflammatory, autoimmune and degenerative diseases Pre-clinical
ARGX-115[9] ABBV-151 AbbVie GARP Cancer immunotherapy Phase I
ARGX-116[6] STT-5058 Staten Biotechnology / Novo Nordisk ApoC3 Dyslipidemia Pre-clinical
ARGX-117[6][7] Broteio Pharma / Prof. Erik Hack, Ph.D C2 Multifocal Motor Neuropathy (MMN) and Kidney indications Phase II
ARGX-118[7] Prof. Bart Lambrecht, M.D. Galectin-10 Airway inflammation Pre-clinical
ARGX-119[7] - MuSK Neuromuscular indications Pre-clinical
ARGX-120[7] - Undisclosed Pre-clinical

References[edit]

  1. ^ a b "Nominees and new location announced for ARIAS 2023". RadioToday. 2023-03-30. Retrieved 2023-04-24.
  2. ^ Bailey, Sam (2023-04-21). "Radio icon Tony Blackburn to receive The Pioneer Award". Radio Academy. Retrieved 2023-04-24.
  3. ^ "Special recognition award for DJ Janice Long to be presented at the ARIAS". On The Radio. Retrieved 2023-04-24.
  4. ^ Bailey, Sam (2023-04-21). "Tim Blackmore MBE will be ARIAS guest of honour". Radio Academy. Retrieved 2023-04-24.
  5. ^ a b "ARGX - argenx SE Company Profile - CNNMoney.com". money.cnn.com. Retrieved 2022-07-07.
  6. ^ a b c d e f g h i j k l m n o p https://www.argenx.com/sites/default/files/report/argenx_report_march_21_2021.pdf
  7. ^ a b c d e f https://www.argenx.com/sites/default/files/media-documents/ARGX_2021_ESG_Report.pdf
  8. ^ a b c d "Finding The Key To Biopharma Start-Up". www.lifescienceleader.com. Retrieved 2022-07-07.
  9. ^ a b c d e https://www.argenx.com/sites/default/files/media-documents/20160602_Registration_Document.pdf
  10. ^ "About". Argenx. Retrieved 2022-07-07.
  11. ^ "Nasdaq Welcomes argenx (Nasdaq: ARGX) to The Nasdaq Stock Market | Nasdaq, Inc". ir.nasdaq.com. Retrieved 2022-07-07.
  12. ^ a b c "Companies To Watch: argenx". www.lifescienceleader.com. Retrieved 2022-07-07.
  13. ^ "arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders". Fierce Biotech. 2013-04-25. Retrieved 2022-07-07.
  14. ^ https://www.argenx.com/sites/default/files/media-documents/argenx_report_2020_March_30_2021.pdf
  15. ^ a b Commissioner, Office of the (2021-12-17). "FDA Approves New Treatment for Myasthenia Gravis". FDA. Retrieved 2022-07-07.
  16. ^ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855644/
  17. ^ a b https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vyvgart
  18. ^ "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov. Retrieved 2022-07-07.
  19. ^ Staff, B. N. S. "Vyvgart (efgartigimod) - Myasthenia Gravis News". Retrieved 2022-07-07.

Further reading[edit]

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Merely_another_passerby/sandbox&oldid=1151612455"